# EDGAR Filing Document

**Accession Number:** 0001450485
**File Stem:** 0001562180-25-005229
**Filing Date:** 2025-7
**Character Count:** 10557
**Document Hash:** fdb194e501bb1375faa3ba1f97da8192
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001562180-25-005229.hdr.sgml**: 20250702

**ACCESSION NUMBER**: 0001562180-25-005229

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250702

**FILED AS OF DATE**: 20250702

**DATE AS OF CHANGE**: 20250702

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lurker Nancy
- **CENTRAL INDEX KEY:** 0001450485

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51122
- **FILM NUMBER:** 251100917

**MAIL ADDRESS:**
- **STREET 1:** CONNAUGHT HOUSE
- **STREET 2:** 1 BURLINGTON ROAD
- **CITY:** DUBLIN 4
- **STATE:** L2
- **ZIP:** D04 C5Y6
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EyePoint Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001314102
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 262774444
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 480 PLEASANT STREET
- **STREET 2:** SUITE C400
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 617-926-5000

**MAIL ADDRESS:**
- **STREET 1:** 480 PLEASANT STREET
- **STREET 2:** SUITE C400
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** pSivida Corp.
- **DATE OF NAME CHANGE:** 20080619

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** pSivida LTD
- **DATE OF NAME CHANGE:** 20050111

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lurker Nancy<br><sub>(Last) (First) (Middle)</sub><br>C/O EYEPOINT PHARMACEUTICALS, INC.<br>480 PLEASANT STREET<br><sub>(Street)</sub><br>WATERTOWN, MA 02472<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>EyePoint Pharmaceuticals, Inc. [ EYPT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $13.13 | 2025-07-02 |  | G<sup>(1)</sup> |  |  | 31165.00 | <sup>(2)</sup> | 2031-02-09 | Common Stock | 31165.00 | $0.00 | 0.00 | D |  |
| Stock Option (Right to Buy) | $13.13 | 2025-07-02 |  | G<sup>(1)</sup> |  | 31165.00 |  | <sup>(2)</sup> | 2031-02-09 | Common Stock | 31165.00 | $0.00 | 213700.00 | I | By Family Trust<sup>(3)</sup> |
| Stock Option (Right to Buy) | $10.13 | 2025-07-02 |  | G<sup>(1)</sup> |  |  | 55000.00 | <sup>(4)</sup> | 2032-02-09 | Common Stock | 55000.00 | $0.00 | 40000.00 | D |  |
| Stock Option (Right to Buy) | $10.13 | 2025-07-02 |  | G<sup>(1)</sup> |  | 55000.00 |  | <sup>(4)</sup> | 2032-02-09 | Common Stock | 55000.00 | $0.00 | 200000.00 | I | By Family Trust<sup>(3)</sup> |
| Stock Option (Right to Buy) | $3.26 | 2025-07-02 |  | G<sup>(1)</sup> |  |  | 103308.00 | <sup>(5)</sup> | 2033-01-05 | Common Stock | 103308.00 | $0.00 | 178442.00 | D |  |
| Stock Option (Right to Buy) | $3.26 | 2025-07-02 |  | G<sup>(1)</sup> |  | 103308.00 |  | <sup>(5)</sup> | 2033-01-05 | Common Stock | 103308.00 | $0.00 | 272358.00 | I | By Family Trust<sup>(3)</sup> |
| Stock Option (Right to Buy) | $9.11 | 2025-07-02 |  | G<sup>(1)</sup> |  |  | 15278.00 | <sup>(6)</sup> | 2033-07-10 | Common Stock | 15278.00 | $0.00 | 34722.00 | D |  |
| Stock Option (Right to Buy) | $9.11 | 2025-07-02 |  | G<sup>(1)</sup> |  | 15278.00 |  | <sup>(6)</sup> | 2033-07-10 | Common Stock | 15278.00 | $0.00 | 31944.00 | I | By Family Trust<sup>(3)</sup> |
| Stock Option (Right to Buy) | $20.40 | 2025-07-02 |  | G<sup>(1)</sup> |  |  | 27270.00 | <sup>(7)</sup> | 2034-01-04 | Common Stock | 27270.00 | $0.00 | 49730.00 | D |  |
| Stock Option (Right to Buy) | $20.40 | 2025-07-02 |  | G<sup>(1)</sup> |  | 27270.00 |  | <sup>(7)</sup> | 2034-01-04 | Common Stock | 27270.00 | $0.00 | 27270.00 | I | By Family Trust<sup>(3)</sup> |

---

### Footnotes:

(1) On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

(2) The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full.

(3) These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

(4) The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.

(5) The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 6, 2027.

(6) The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until July 10, 2027.

(7) The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 5, 2028.

**Signature:** /s/ Ron Honig, Attorney-in-Fact  
**Date:** 2025-07-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**